Posts tagged Piramal Pharma
Latest Research Reports On Stocks By Leading Brokerages: If you have any research reports that you would like to share with us, please send it to michael@rakesh-jhunjhunwala.in or to admin@rakesh-jhunjhunwala.in. (The pre-June 2016 reports are available here).
| Buy Piramal Pharma for Target Price of Rs 200 (42% Upside): ICICI Securities | |
| Company: | Piramal Pharma |
| Brokerage: | ICICI Securities |
| Date of report: | November 14, 2022 |
| Type of Report: | Result Update |
| Recommendation: | Buy |
| Upside Potential: | 42% |
| Summary: | We remain positive on Piramal Pharma considering the growing requirement for development services, especially with complex regulatory processes for newer drugs, high entry barriers, limited competition for the complex hospital generics (provides sustainable growth over the longer term) and the rising contribution from the fast growing consumer segment. We initiate coverage post demerger with a BUY rating and an SoTP-based target price of Rs200/share |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | ICICI Securities |